Excaliard Pharmaceuticals, Inc.

Isis Pharmaceuticals, Inc.

Shire Human Genetic Therapies, Inc.

Ionis Pharmaceuticals, Inc.

Lumena Pharmaceutials LLC

Lumena Pharmaceuticals LLC

Niall O'Donnell

Nicholas M Dean

J Gordon Foulkes

C Frank Bennett

Bronislava Gedulin

Michael Grey

Susan M Frier

Susan M Freier

Gregory E Hardee

Leroy Young

Mark Jewell

Lincoln Krochmal

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.

Antisense oligonucleotides directed against connective tissue growth factor and uses thereof

This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.

Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)

Methods for inhibiting expression of connective tissue growth factor

Growing community of inventors

Encinitas, CA, United States of America

Niall O'Donnell